1575.00
2.01%
Prabhudas Lilladhar
One-off sales of CQ and HCQS to impact growth and margin in FY22E We increase our earnings estimates by 9.7%/7.7% for FY22E/23E while revenue cut by 3.3%/3.1% in FY22E/FY23E. Expansion in EBITDA margins by 170bps to 25.2% (management guidance of 25.0-25.5%) due to reduction in...
Number of FII/FPI investors decreased from 270 to 254 in Sep 2025 qtr
More from Ipca Laboratories Ltd.
Recommended